European Approval for Mynzepli Biosimilar to Eylea for Retinal Diseases
ByAinvest
Thursday, Aug 21, 2025 4:30 am ET1min read
ALVO--
Alvotech and Advanz Pharma have received European approval for Mynzepli, a biosimilar to Eylea, for treating various retinal diseases including neovascular age-related macular degeneration. Approval is based on comprehensive data, including a confirmatory efficacy study comparing Mynzepli with Eylea in patients with neovascular AMD. Mynzepli will be available in pre-filled syringes and vials.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet